$59.20
-0.04-0.07%
Pre-Market: Sep 20, 5:26 PM EDT
15 minutes delayed
Halozyme Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Halozyme Therapeutics using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-06 | $0.91 | $0.78 | 16.7 % |
Mar 2024 | 2024-05-07 | $0.79 | $0.69 | 14.5 % |
Dec 2023 | 2024-02-20 | $0.82 | $0.83 | -1.20 % |
Sep 2023 | 2023-11-06 | $0.75 | $0.73 | 2.74 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-06 | $231.35M | $208.94M | 10.7 % |
Mar 2024 | 2024-05-07 | $195.88M | $199.78M | -1.95 % |
Dec 2023 | 2024-02-20 | $230.04M | $233.19M | -1.35 % |
Sep 2023 | 2023-11-06 | $216.03M | $222.63M | -2.96 % |
Halozyme Therapeutics (HALO) is scheduled to report earnings on November 4, 2024. The last reported earnings were for reported on August 6, 2024 for Q2.
The Actual EPS was $0.91, which beat the estimate of $0.78.
The Actual Revenue was $231.4M, which beat the estimate of $208.9M.
Browse earnings estimates, EPS, and revenue on all stocks.